Adaptin Bio, Inc. SEC filings APTN
Adaptin Bio, Inc. has 75 filings in SEC EDGAR's recent list, going back to Aug 10, 2023. Its latest annual report, Form 10-K, was filed on Apr 1, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 25, 2026 (other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 424B3 | Prospectus | Sep 10, 2026 | — |
| EFFECT | Filing | Sep 9, 2026 | — |
| S-1 | Registration statement | Aug 28, 2026 | — |
| 424B3 | Prospectus | Aug 25, 2026 | — |
| 8-K |
Current report
Other events
|
Aug 25, 2026 | Aug 20, 2026 |
| 424B3 | Prospectus | Aug 20, 2026 | — |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| EFFECT | Filing | Jul 22, 2026 | — |
| POS AM | Post-effective amendment no. 1 to form s-1 | Jul 21, 2026 | — |
| D/A | Filing | Jun 22, 2026 | — |
| 424B3 | Prospectus | Jun 12, 2026 | — |
| 10-K/A | Amended annual report | Jun 12, 2026 | Dec 31, 2025 |
| 424B3 | Prospectus | May 18, 2026 | — |
| 10-Q | Quarterly report | May 15, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Other events
|
Apr 6, 2026 | Apr 6, 2026 |
| 10-K | Annual report | Apr 1, 2026 | Dec 31, 2025 |
| NT 10-K | Notification of late filing | Apr 1, 2026 | Dec 31, 2025 |
| D/A | Filing | Mar 23, 2026 | — |
| D/A | Filing | Feb 20, 2026 | — |
| D | Filing | Jan 5, 2026 | — |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Dec 23, 2025 | Dec 22, 2025 |
| 424B3 | Prospectus | Nov 17, 2025 | — |
| 10-Q | Quarterly report | Nov 14, 2025 | Sep 30, 2025 |
| 424B3 | Prospectus | Oct 7, 2025 | — |
| 8-K |
Current report
Officer or director change, Other events
|
Oct 6, 2025 | Oct 3, 2025 |
| 4 | Insider transaction | Sep 10, 2025 | Sep 8, 2025 |
| 4 | Insider transaction | Sep 10, 2025 | Sep 8, 2025 |
| 4 | Insider transaction | Sep 10, 2025 | Sep 8, 2025 |
| 4 | Insider transaction | Sep 10, 2025 | Sep 8, 2025 |
| 4 | Insider transaction | Sep 10, 2025 | Sep 8, 2025 |
| 4 | Insider transaction | Sep 10, 2025 | Sep 8, 2025 |
| 4 | Insider transaction | Sep 10, 2025 | Sep 8, 2025 |
| S-8 | Employee stock plan registration | Aug 15, 2025 | — |
| 424B3 | Prospectus | Aug 15, 2025 | — |
| 10-Q | Quarterly report | Aug 14, 2025 | Jun 30, 2025 |
| 424B3 | Prospectus | Aug 5, 2025 | — |
| EFFECT | Filing | Aug 4, 2025 | — |
| CORRESP | Letter to the SEC | Jul 31, 2025 | — |
| CORRESP | Letter to the SEC | Jul 28, 2025 | — |
| S-1/A | Amended registration statement | Jul 28, 2025 | — |
| UPLOAD | Letter from the SEC | Jul 16, 2025 | — |
| CORRESP | Letter to the SEC | Jun 27, 2025 | — |
| S-1/A | Amended registration statement | Jun 27, 2025 | — |
| UPLOAD | Letter from the SEC | Jun 13, 2025 | — |
| S-1 | Registration statement | May 16, 2025 | — |
| 10-Q | Quarterly report | May 15, 2025 | Mar 31, 2025 |
| 10-K | Annual report | Apr 15, 2025 | Dec 31, 2024 |
| 8-K/A |
Amended current report
Acquisition or sale of assets
|
Apr 15, 2025 | Feb 11, 2025 |
| 8-K |
Current report
Other events
|
Apr 9, 2025 | Apr 7, 2025 |
| NT 10-K | Notification of late filing | Mar 31, 2025 | Dec 31, 2024 |
| D | Filing | Feb 26, 2025 | — |
| SCHEDULE 13D | Ownership over 5% (active) | Feb 18, 2025 | — |
| SCHEDULE 13D | Ownership over 5% (active) | Feb 18, 2025 | — |
| 3 | Initial insider ownership | Feb 18, 2025 | Feb 11, 2025 |
| 3 | Initial insider ownership | Feb 18, 2025 | Feb 11, 2025 |
| 3 | Initial insider ownership | Feb 18, 2025 | Feb 11, 2025 |
| 3 | Initial insider ownership | Feb 18, 2025 | Feb 11, 2025 |
| 3 | Initial insider ownership | Feb 18, 2025 | Feb 11, 2025 |
| 3 | Initial insider ownership | Feb 18, 2025 | Feb 11, 2025 |
| 3 | Initial insider ownership | Feb 18, 2025 | Feb 11, 2025 |
| 8-K |
Current report
Material agreement, Acquisition or sale of assets, Unregistered share sale, Change to shareholder rights, Auditor change, Change in control, Officer or director change, Bylaw or fiscal year change
|
Feb 18, 2025 | Feb 11, 2025 |
| 4 | Insider transaction | Feb 13, 2025 | Feb 11, 2025 |
| SC 14F1 | Schedule 14f-1 | Jan 29, 2025 | — |
| 10-Q | Quarterly report | Nov 14, 2024 | Sep 30, 2024 |
| 10-Q | Quarterly report | Aug 14, 2024 | Jun 30, 2024 |
| 10-Q | Quarterly report | May 15, 2024 | Mar 31, 2024 |
| 10-K | Annual report | Apr 1, 2024 | Dec 31, 2023 |
| 3 | Initial insider ownership | Nov 30, 2023 | Oct 9, 2023 |
| 3 | Initial insider ownership | Nov 30, 2023 | Oct 9, 2023 |
| UPLOAD | Letter from the SEC | Nov 20, 2023 | — |
| 10-Q | Quarterly report | Nov 14, 2023 | Sep 30, 2023 |
| CORRESP | Letter to the SEC | Oct 6, 2023 | — |
| 10-12G/A | Amendment no.1 to form 10-12g | Oct 6, 2023 | — |
| UPLOAD | Letter from the SEC | Sep 7, 2023 | — |
| 10-12G | General form for registration of securities | Aug 10, 2023 | — |
Showing 75 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- APTN (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Charlotte, NC
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1938571
- Former names
- Unite Acquisition 1 Corp. (until Feb 13, 2025)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.